Ayala Entered into a Definitive Merger Agreement with Advaxis for AL102 and ADXS-504
Shots:
- Under the merger agreement, each outstanding share of Ayala common stock will be converted into the right to receive 0.1874 shares of common stock of Advaxis. The transaction is expected to close in Q1’23
- Ayala stockholders will own ~62.5% & Advaxis stockholders will own ~37.5% of the combined company’s outstanding common stock. Advaxis will be renamed “Ayala Pharmaceuticals, Inc”
- The combined company focuses on Ayala’s AL102, currently in P-II/III (RINGSIDE) study for desmoid tumors & Advaxis’s ADXS-504 for prostate cancer. The agreement will also accelerate Advaxis’s portfolio of Ayala’s gamma-secretase inhibitor, being developed as targeted therapies for rare & aggressive tumors
Ref: Globe Newswire | Image: Ayala
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
